{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:07Z","timestamp":1791456667535,"version":"4.3.4"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005971","name":"German Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Foundation of Heart Research"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aldosterone dysregulation is a key driver of difficult-to-control and resistant hypertension. Mineralocorticoid receptor antagonists (MRAs) target the aldosterone pathway but their use can be limited by side effects, particularly hyperkalemia and antiandrogenic hormonal effects. Selective aldosterone synthase inhibitors (ASIs) have shown clinically meaningful blood pressure reductions in patients with difficult-to-control and resistant hypertension in recent phase 2b and 3 trials. In this narrative review, we summarize pivotal evidence from phase 2b and phase 3 trials of the second-generation ASIs lorundrostat, baxdrostat, and dexfadrostat, reporting efficacy and core safety signals (hyperkalemia, hyponatremia, and an early functional reduction in estimated glomerular filtration rate (eGFR]). We further discuss the implications of these findings, economic and access considerations, remaining evidence gaps, future research directions, and potential practical treatment algorithms. ASIs offer clinically significant blood pressure lowering with moderate side effects when added on top of current therapies in short-term trials, though long-term outcome data are lacking. In May 2026, the US Food and Drug Administration (FDA) approved the first ASI, baxdrostat, for hypertension treatment in combination with other antihypertensive drugs in inadequately controlled adults. However, gaps remain, most notably the absence of comparative effectiveness trials versus MRAs, the standard fourth-line agent. ASIs target upstream aldosterone production and may offer a distinct, complementary role for patients with intolerance or contraindications for MRA or insufficient response. ASIs may be best reserved for the treatment of uncontrolled or resistant hypertension in combination with other antihypertensives and where MRAs are contraindicated, poorly tolerated, or insufficient.<\/jats:p>","DOI":"10.1093\/ajh\/hpag083","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:39:45Z","timestamp":1784029185000},"page":"S30-S42","source":"Crossref","is-referenced-by-count":0,"title":["The hypertension specialist\u2019s perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4998-1817","authenticated-orcid":false,"given":"Romina Ruth","family":"Diaz","sequence":"first","affiliation":[{"name":"The George Institute for Global Health , Sydney, NSW,","place":["Australia"]},{"name":"School of Population Health, University of New South Wales , Sydney, NSW,","place":["Australia"]},{"name":"Programa de Prevenci\u00f3n Cardiovascular, Lezica Instituto Cardiovascular , San Isidro,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-624X","authenticated-orcid":false,"given":"Amelie H","family":"Ohlrogge","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health , Sydney, NSW,","place":["Australia"]},{"name":"Department of Cardiology, University Heart and Vascular Center Hamburg , Hamburg,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site North , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-4937","authenticated-orcid":false,"given":"Aletta E","family":"Schutte","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health , Sydney, NSW,","place":["Australia"]},{"name":"School of Population Health, University of New South Wales , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806022552800_hpag083-B1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Global Cardiovascular Risk Factor Consortium","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100806022552800_hpag083-B2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"2026100806022552800_hpag083-B3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2026100806022552800_hpag083-B4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"2026100806022552800_hpag083-B5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2026100806022552800_hpag083-B6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806022552800_hpag083-B7","doi-asserted-by":"publisher","first-page":"102385","DOI":"10.1016\/j.jacadv.2025.102385","article-title":"Occurrence and patient characteristics of aldosterone dysregulation in routine clinical care: a population-based study","volume":"5","author":"Ljungberg","year":"2026","journal-title":"JACC Adv"},{"key":"2026100806022552800_hpag083-B8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/hr.2013.74","article-title":"Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist","volume":"36","author":"Sato","year":"2013","journal-title":"Hypertens Res"},{"key":"2026100806022552800_hpag083-B9","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2215\/CJN.06960712","article-title":"Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy","volume":"8","author":"Moranne","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100806022552800_hpag083-B10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","article-title":"Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus","volume":"20","author":"Yoneda","year":"2007","journal-title":"Am J Hypertens"},{"key":"2026100806022552800_hpag083-B11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1291\/hypres.31.363","article-title":"Aldosterone nongenomically produces NADPH oxidase\u2013dependent reactive oxygen species and induces myocyte apoptosis","volume":"31","author":"Hayashi","year":"2008","journal-title":"Hypertens Res"},{"key":"2026100806022552800_hpag083-B12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","article-title":"Non-genomic actions of aldosterone: from receptors and signals to membrane targets","volume":"350","author":"Dooley","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026100806022552800_hpag083-B13","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"2026100806022552800_hpag083-B14","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1161\/hypertensionaha.125.25104","article-title":"Adrenalectomy versus medical therapy in primary aldosteronism: a meta-analysis of long-term cardiac remodeling and function: Medical versus adrenalectomy treatment compared in hyperaldosteronism (MATCH) study","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"2026100806022552800_hpag083-B15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an Add-On therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens"},{"key":"2026100806022552800_hpag083-B16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/circulationaha.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"2026100806022552800_hpag083-B17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"2026100806022552800_hpag083-B18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806022552800_hpag083-B19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"key":"2026100806022552800_hpag083-B20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806022552800_hpag083-B21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100806022552800_hpag083-B22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0140-6736(25)00991-2","article-title":"Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"2026100806022552800_hpag083-B23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/hypertensionaha.113.02026","article-title":"Refractory hypertension","volume":"63","author":"Calhoun","year":"2014","journal-title":"Hypertension"},{"key":"2026100806022552800_hpag083-B24","doi-asserted-by":"publisher","first-page":"e25659","DOI":"10.1161\/HYPERTENSIONAHA.125.25659","article-title":"Contemporary prevalence and treatment patterns among US adults with apparent treatment-resistant hypertension","volume":"83","author":"Earle","year":"2026","journal-title":"Hypertension"},{"key":"2026100806022552800_hpag083-B25","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"2026100806022552800_hpag083-B26","volume-title":"Global Report on Hypertension 2025: High Stakes - Turning Evidence into Action","author":"World Health Organization","year":"2025"},{"key":"2026100806022552800_hpag083-B27","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the european society of hypertension: endorsed by the international society of hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026100806022552800_hpag083-B28","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100806022552800_hpag083-B29","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1161\/CIR.0000000000001356","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"152","author":"Jones","year":"2025","journal-title":"Circulation"},{"key":"2026100806022552800_hpag083-B30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3399\/bjgp24X736390","article-title":"Specialist hypertension clinics: an essential pathway but under-resourced","volume":"74","author":"McCormack","year":"2024","journal-title":"Br J Gen Pract"},{"key":"2026100806022552800_hpag083-B31","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/jama.2026.1221","article-title":"Diagnosis and management of resistant hypertension: a review","volume":"335","author":"Azizi","year":"2026","journal-title":"JAMA. Published"},{"key":"2026100806022552800_hpag083-B32","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806022552800_hpag083-B33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41440-026-02578-9","article-title":"Cost-effectiveness of renal denervation: a systematic review and meta-analysis","volume":"49","author":"Kyriakoulis","year":"2026","journal-title":"Hypertens Res"},{"key":"2026100806022552800_hpag083-B34","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.26633\/RPSP.2022.150","article-title":"Integrating hypertension and diabetes management in primary health care settings: HEARTS as a tool","volume":"46","author":"Flood","year":"2022","journal-title":"Rev Panam Salud P\u00fablica."},{"key":"2026100806022552800_hpag083-B35","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.2025.16167","article-title":"Lorundrostat for uncontrolled hypertension and treatment-resistant hypertension","volume":"334","author":"Tai","year":"2025","journal-title":"JAMA"},{"key":"2026100806022552800_hpag083-B36","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/hypertensionaha.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"2026100806022552800_hpag083-B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026100806022552800_hpag083-B38","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","article-title":"Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles","volume":"16","author":"Danjuma","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"2026100806022552800_hpag083-B39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/circulationaha.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation"},{"key":"2026100806022552800_hpag083-B40","doi-asserted-by":"publisher","first-page":"e21694","DOI":"10.1097\/MD.0000000000021694","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026100806022552800_hpag083-B41","doi-asserted-by":"publisher","first-page":"CD008169","DOI":"10.1002\/14651858.CD008169.pub2","article-title":"Spironolactone for hypertension","volume":"8","author":"Batterink","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100806022552800_hpag083-B42","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"2026100806022552800_hpag083-B43","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]) see appendix for full list of RALES investigators","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"2026100806022552800_hpag083-B44","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100806022552800_hpag083-B45","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.jacc.2025.12.091","article-title":"Global hypertension 2000 to 2020","volume":"87","author":"O\u2019Connell","year":"2026","journal-title":"JACC"},{"key":"2026100806022552800_hpag083-B46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/cvr\/cvac130","article-title":"Addressing global disparities in blood pressure control: perspectives of the international society of hypertension","volume":"119","author":"Schutte","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026100806022552800_hpag083-B47","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026100806022552800_hpag083-B48","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806022552800_hpag083-B49","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: a scientific statement from the American heart association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"},{"key":"2026100806022552800_hpag083-B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102576","article-title":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","volume":"71","author":"Mulatero","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"2","key":"2026100806022552800_hpag083-B51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008996.pub2","article-title":"Eplerenone for hypertension","author":"Tam","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"2026100806022552800_hpag083-B52","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"2026100806022552800_hpag083-B53","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"2026100806022552800_hpag083-B54","doi-asserted-by":"publisher","first-page":"6683987","DOI":"10.1155\/2023\/6683987","article-title":"Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis","volume":"2023","author":"Hu","year":"2023","journal-title":"International Journal of Hypertension"},{"issue":"1","key":"2026100806022552800_hpag083-B55","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"2026100806022552800_hpag083-B56","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","article-title":"Drug-Induced Hyperkalemia","volume":"37","author":"Ben","year":"2014","journal-title":"Drug Safety"},{"issue":"23","key":"2026100806022552800_hpag083-B57","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.2025.5129","article-title":"Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial","volume":"333","author":"Lee","year":"2025","journal-title":"JAMA"},{"key":"2026100806022552800_hpag083-B58","author":"Price of eplerenone on drugs.com"},{"key":"2026100806022552800_hpag083-B59","author":"Price of finerenone on drugs.com"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S30\/71667110\/hpag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S30\/71667110\/hpag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:02:34Z","timestamp":1791453754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S30\/8875941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":59,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag083","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}